Evaluating Targeted NGS Readiness for ICU Severe Pneumonia Diagnosis

Overview

This interim analysis of 51 ICU patients with severe pneumonia compared targeted next-generation sequencing (tNGS) using RPIP to conventional microbiological tests (CMT) combined with the FilmArray Pneumonia Panel (FAPP). While tNGS showed a higher overall detection rate, adjudicated causative pathogen identification was similar between methods, highlighting challenges in routine ICU implementation.

Background

Severe pneumonia in ICU patients requires rapid and accurate pathogen identification to guide therapy. Targeted next-generation sequencing (tNGS) offers broader pathogen and antimicrobial resistance (AMR) gene detection compared to conventional microbiological tests (CMT) and molecular assays like FAPP. However, barriers such as clinical feasibility, interpretation of results, and impact on patient management have limited its routine use. This study evaluates the diagnostic yield and clinical utility of tNGS in a real-world ICU setting.

Data Highlights

Notably, 45.1% (23/51) of cases had no adjudicated causative pathogen identified by any method.

Key Findings

• RPIP detected pathogens in 90.2% of cases versus 82.4% for standard testing, but adjudicated causative pathogen identification was similar (47.1% vs 49.0%).
• No statistically significant difference in causative pathogen detection between RPIP and CMT + FAPP (p = 1.00).
• RPIP provided additional clinically actionable information in 23.5% of patients, mainly related to antimicrobial resistance gene detection.
• Nearly half of patients (45.1%) had no causative pathogen identified, underscoring the challenge of non-infectious mimics of pneumonia.
• Median turnaround time for tNGS was 6.5 days, limiting its use as a rapid diagnostic tool in ICU settings.
• Discrepancies between genotypic AMR markers and phenotypic susceptibility remain common, complicating antimicrobial stewardship decisions.

Clinical Implications

While tNGS expands pathogen and AMR gene detection, its current turnaround time and interpretation challenges limit routine ICU use as a frontline diagnostic tool. Clinicians should consider tNGS as an adjunct, particularly in complex or immunocompromised patients where conventional testing is inconclusive. Multidisciplinary review of negative or discordant results may help avoid unnecessary broad-spectrum antibiotic use and guide antimicrobial stewardship.

Conclusion

Targeted NGS demonstrates promising diagnostic capabilities for severe pneumonia in ICU patients but does not yet surpass standard testing in identifying adjudicated causative pathogens. Addressing workflow, interpretation, and clinical integration challenges is essential before widespread routine implementation.

References

1. Li et al. 2023 -- Barriers to Routine Molecular Diagnostics
2. Wu et al. 2023 -- Challenges in Clinical Translation of NGS
3. Chen et al. 2023 -- Diagnostic Yield of NGS in Immunocompromised Patients
4. Charalampous et al. 2023 -- Rapid Respiratory Metagenomics in ICU
5. Kalantar et al. 2023 -- Integrating Host Transcriptional Profiling with Metagenomics